FDA approves Gazyva to treat follicular lymphoma
1 March 2016 | By Victoria White
The FDA has approved Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma...
List view / Grid view
News
Quotient Clinical showcases Enabled-First-in-Human® programs at ASCPT 2016
1 March 2016 | By Quotient Clinical
Quotient Clinical will be showcasing its Enabled-First-in-Human® programs at the upcoming ASCPT Meeting 2016...
ProStrakan reaches deal for Moventig with AstraZeneca
1 March 2016 | By Victoria White
ProStrakan will make an upfront payment to AstraZeneca of $70 million to acquire the rights to Moventig in the EU, Iceland, Norway, Switzerland and Liechtenstein...
CHMP adopts positive opinion of afatinib in SqCC
29 February 2016 | By Victoria White
The CHMP positive opinion is based on the results of the head-to-head LUX-Lung 8 trial in patients with SqCC...
New modern and specialized R&D and Test Center
29 February 2016 | By F.P.S. Food and Pharma Systems Srl
FPS is pleased to announce the opening of his new R&D and Test Center...
Celgene’s Imnovid and Abraxane recommended for use in Ireland
29 February 2016 | By Victoria White
Celgene has announced that that of the Health Service Executive (HSE) of Ireland has recommended two cancer treatments: Imnovid and Abraxane...
Tremelimumab mesothelioma trial fails to meet primary endpoint
29 February 2016 | By Victoria White
DETERMINE, the Phase IIb clinical trial of tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival...
Future proofing – Part 1. Modularity and flexibility – New LAB.line tablet hardness testers
29 February 2016 | By Arwid Ischi, Charles Ischi AG | Kraemer Elektronik
What requirements need to be met by a tablet testing system to guarantee a successful product release? Is it dependable upon the testing system’s quality, speed, technology, flexibility or safety? Kraemer and Ischi explain...
Boehringer Ingelheim launches two initiatives to help those living with IPF
29 February 2016 | By Victoria White
Boehringer Ingelheim's new initiatives are dedicated to raising awareness of IPF, a rare disease that is frequently misdiagnosed and little understood...
Roche provides update on two Phase III studies of lebrikizumab in asthma
29 February 2016 | By Victoria White
LAVOLTA I and II are two identical, randomised, multicentre, placebo-controlled Phase III studies designed to evaluate the efficacy and safety of lebrikizumab...
Brivaracetam launches in the UK as a new option for patients with uncontrolled epilepsy
29 February 2016 | By Victoria White
UCB’s Briviact (brivaracetam) has been authorised in the UK as an add-on treatment for partial onset seizures with or without secondary generalised seizures...
Industrial pharmaceutical sieves for powders at GSK
GlaxoSmithKline is improving process efficiency in the production of pharmaceutical powders at its “centre of excellence” plant in Dartford, Kent, by investing in nine new industrial pharmaceutical sieves fitted with the Vibrasonic® Deblinding System from Russell Finex...
CHMP adopts positive opinion of AbbVie’s Viekirax + Exviera in HCV
26 February 2016 | By Victoria White
The CHMP opinion of the Type-II variation application for Viekirax + Exviera is supported by data from the Phase 3b TURQUOISE-III study...
CHMP adopts positive opinion for Lilly’s ixekizumab
26 February 2016 | By Victoria White
Ixekizumab is an IgG4 monoclonal antibody that selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor...
CHMP adopts positive opinion of Opdivo in NSCLC and RCC
26 February 2016 | By Victoria White
Both indications are supported by Phase 3 studies in which Opdivo demonstrated a survival benefit versus a standard of care...
